ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
- Conditions
- Breast NeoplasmsMetastases, Neoplasm
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00046514
- Locations
- ๐บ๐ธ
Abraxis BioScience, Inc., Raleigh, North Carolina, United States
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
- Conditions
- Breast NeoplasmsMetastases, Neoplasm
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2006-07-13
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 460
- Registration Number
- NCT00046527
- Locations
- ๐บ๐ธ
Abraxis Bioscience, Inc, Durham, North Carolina, United States
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00046735
- Locations
- ๐บ๐ธ
Wake Forest University, Winston-Salem, North Carolina, United States
Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes
- First Posted Date
- 2002-09-11
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT00045786
- Locations
- ๐บ๐ธ
Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois, United States
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2002-08-29
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00044382
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00044018
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธSt Vincent's Cancer Center, New York, New York, United States
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Colorectal NeoplasmsDiarrhea
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00040391
- Locations
- ๐บ๐ธ
Research Center, Milwaukee, Wisconsin, United States
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
- Conditions
- HIV InfectionsHIV Wasting Syndrome
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT00002127
- Locations
- ๐บ๐ธ
Marin County Specialty Clinic, Greenbrae, California, United States
๐บ๐ธGottlieb Med Group, Sherman Oaks, California, United States
๐บ๐ธGeorge Washington Univ Med Ctr, Washington, District of Columbia, United States
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
- Conditions
- HIV InfectionsHIV Wasting Syndrome
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00002157
- Locations
- ๐บ๐ธ
Celgene Corp, Warren, New Jersey, United States